Biotechnology

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...

2024-11-18 21:50 1186

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo)...

2024-11-18 21:01 1161

FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection

BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate, Libevitug (HH-00...

2024-11-18 18:40 944

New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence

New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership withHealthcare Executi...

2024-11-18 16:00 1162

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

* Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering * Robust and sustainable treatment effects support at least bi-annual dosing regimen * Best-in-class potential of novel PC...

2024-11-18 09:00 1702

Boehringer Ingelheim Commits to Veeva Vault CRM

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim is the latest global to...

2024-11-18 09:00 1133

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

TEL AVIV, Israel, Nov. 18, 2024 /PRNewswire/ -- SoniVie Ltd. , a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment ofRaymond W. Cohen to serve as its chairman of the board of directors. Mr. Coh...

2024-11-18 09:00 830

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd. , a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment ofRaymond W. Cohen to serve as its chairman of the board of directors. Mr. Coh...

2024-11-18 08:00 783

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA

ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a New Drug Applica...

2024-11-17 22:24 1452

Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth

- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership - Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neuroph...

2024-11-15 22:00 1487

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program  * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...

2024-11-15 20:00 1204

Angel Yeast Turns Automation into Opportunity, Ensuring No Job Losses

YICHANG, China, Nov. 15, 2024 /PRNewswire/ -- Angel Yeast has taken a significant step towards modernization and sustainability by automating its packaging line while ensuring no layoffs for its employees. In 2024, with the completion of the intelligent transformation of its packaging workshop, t...

2024-11-15 20:00 1189

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-11-15 09:55 1151

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 15, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGM...

2024-11-14 23:45 838

I-Mab Reports Third Quarter 2024 Results

* Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data * On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 * Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 * Estimated cash ru...

2024-11-14 20:00 929

Ubiquity Sprouting Corporation Unveils Prototype for Revolutionary Germinated Plant Milk Production System

TAIPEI, Nov. 14, 2024 /PRNewswire/ -- Ubiquity Sprouting Corporation has achieved a major milestone in the plant-based milk industry, completing the prototype of its innovative germinated plant milk production equipment. This cutting-edge technology, designed to work seamlessly with Ubiquity's s...

2024-11-14 15:57 1250

Breakthrough Research Presented in Scientific Reports Demonstrates How Gene-Edited Microbes Offer a New Source of Nitrogen to Farmers

Findings are the first, peer-reviewed evidence of gene-edited microbes supplying a material proportion of corn farmers' nitrogen in commercial production  BERKELEY, Calif., Nov. 14, 2024 /PRNewswire/ -- Peer-reviewed research published today in Scientific Reports describes a new technology ...

2024-11-14 05:42 1246

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...

2024-11-13 23:51 988

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery, is excited to announce its official launch. The com...

2024-11-13 20:30 1184

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement withBerlin -based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotro...

2024-11-13 16:18 1469
12345 ... 306